CriticalSelective irreversible MAO-B inhibitor×Triptan, selective 5HT1B/1D receptor agonist
Updated · Methodology
Mechanism
At recommended doses, selegiline inhibits monoamine oxidase type B (MAO-B) selectively and irreversibly, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4, 5.1 and 5.2). Zolmitriptan stimulates serotonin 5-HT1B and 5-HT1D receptors involved in vascular constriction (zolmitriptan SmPC, AEMPS, section 5.1). Its own metabolism depends on the enzyme CYP1A2, and monoamine oxidase type A metabolises its active metabolite N-desmethylzolmitriptan (zolmitriptan SmPC, AEMPS, section 5.2). Selegiline did not change the pharmacokinetics of zolmitriptan: in a study, selegiline 10 mg a day for one week had no effect on the pharmacokinetics of zolmitriptan or its metabolite (zolmitriptan SmPC, AEMPS, section 4.5; zolmitriptan label, US Food and Drug Administration, FDA, section 12.3). The contraindication in the selegiline SmPC rests on a different risk: serious interactions, up to serotonin syndrome, with serotonin agonists, zolmitriptan among them (selegiline SmPC, AEMPS, section 4.5).
Symptoms
The prescribing information does not describe how this particular combination presents. However, the selegiline summary of product characteristics (SmPC) warns that serious interactions with serotonin agonists can lead to serotonin syndrome (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). According to the zolmitriptan SmPC, serotonin syndrome is potentially life-threatening. In a person taking a serotonergic drug, the diagnosis is likely if any of the following is present: spontaneous clonus; inducible ocular clonus with agitation and sweating; tremor and hyperreflexia; or increased muscle tone with a body temperature above 38 °C and inducible ocular clonus (AEMPS, section 4.4). According to the US Food and Drug Administration (FDA) zolmitriptan label, triptans can cause serotonin syndrome, particularly with antidepressants or monoamine oxidase (MAO) inhibitors. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (section 5.7). Zolmitriptan itself can cause heaviness, tightness, pain or pressure in the throat, neck, limbs or chest, palpitations and transient rises in blood pressure, and very rarely coronary artery spasm, angina and myocardial infarction (zolmitriptan SmPC, AEMPS, sections 4.4 and 4.8).
Management
The combination is contraindicated. The selegiline summary of product characteristics (SmPC) lists serotonin agonists among contraindicated combinations and names zolmitriptan (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The Spanish zolmitriptan SmPC and the US Food and Drug Administration (FDA) zolmitriptan label do not list selegiline among their contraindications. According to them, selegiline, a selective monoamine oxidase type B (MAO-B) inhibitor, does not change zolmitriptan pharmacokinetics. Their restrictions apply only to MAO type A inhibitors. The Spanish SmPC limits zolmitriptan to 5 mg in 24 hours with these inhibitors (AEMPS, sections 4.2 and 4.5). The FDA label contraindicates zolmitriptan during their use and within 2 weeks of stopping them (sections 4 and 7.2). This does not lift the contraindication in the selegiline SmPC, which gives the risk of serious interactions, up to serotonin syndrome, as the reason (AEMPS, section 4.5). No document gives an interval between stopping selegiline and the first dose of zolmitriptan, or for the opposite switch. Selegiline inhibits MAO-B irreversibly, and after a single 10 mg dose platelet MAO-B activity returns to normal in about 2 weeks (selegiline SmPC, AEMPS, section 5.2). If the two drugs have nevertheless been taken together and signs of serotonin syndrome appear, stop zolmitriptan (FDA zolmitriptan label, section 5.7). Stopping serotonergic drugs brings rapid improvement, and treatment depends on the nature and severity of the symptoms (zolmitriptan SmPC, AEMPS, section 4.4). Monitor blood pressure during zolmitriptan treatment (FDA zolmitriptan label, section 5.8). Zolmitriptan is contraindicated in moderate or severe hypertension and in uncontrolled mild hypertension (zolmitriptan SmPC, AEMPS, section 4.3). If chest pain or other signs of cardiac ischaemia appear, withhold further doses until the patient has been assessed (zolmitriptan SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- AEMPS: Ficha técnica: Zolmitriptán, Zomig 2,5 mg (nº registro 61826), sección 4.5 (2022)– AEMPS, CIMA, nº registro 61826, revisión 05/2022, secciones 4.2 y 4.5
- FDA: Zomig (zolmitriptan) prescribing information (2024)– FDA, DailyMed, setid 1d977430-f494-415d-9daf-3c3163156249, Amneal Pharmaceuticals, revisión 02/2024, secciones 4, 5.7 y 7.2